

## About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

### Spherix Provides Independent Expertise in Seven Areas



**Dermatology**



**Nephrology**



**Gastroenterology**



**Neurology**



**Rheumatology**



**Ophthalmology**



**Hematology**

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

### Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

## Type of Publications

### MARKET DYNAMIX

*A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.*

### REALTIME DYNAMIX

*A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.*

### LAUNCH DYNAMIX

*Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.*

### PATIENT CHART DYNAMIX

*A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmask real patient management patterns and uncovers the "why" behind treatment decisions.*

### SPECIAL TOPIX

*Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.*

For a complete index of available reports, visit  
[www.clientportal.spherixglobalinsights.com](http://www.clientportal.spherixglobalinsights.com)



## Atopic Dermatitis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Atopic Dermatitis, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Atopic Dermatitis, EU5</li> <li>Atopic Dermatitis, JP/ CH</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Ebglyss (Eli Lilly) in Atopic Dermatitis, US</li> <li>Nemluvio (Galderma) in Atopic Dermatitis, US</li> <li>Vtama and Zoryve (Arcutis/ Dermavant) in Atopic Dermatitis, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Atopic Dermatitis, US</li> </ul>

## Alopecia Areata

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Alopecia Areata, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Leqselvi (SUN Pharma) in Alopecia Areata, US</li> <li>Litfulo (Pfizer) in Alopecia Areata, US</li> </ul>

## Hidradenitis Suppurativa

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hidradenitis Suppurativa, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hidradenitis Suppurativa, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Bimzelx (UCB) in Hidradenitis Suppurativa, US*</li> <li>Cosentyx (Novartis) in Hidradenitis Suppurativa, US</li> </ul>

## Dermatology Related Respiratory

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Asthma, US</li> <li>Chronic Spontaneous Urticaria, US</li> </ul>
-----------------------	---

## Plaque Psoriasis

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Plaque Psoriasis, US</li> <li>Plaque Psoriasis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Bimzelx (UCB) in Plaque Psoriasis, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Plaque Psoriasis, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>The Oral Opportunity in Plaque Psoriasis, US</li> </ul>

## Other Dermatology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Prurigo Nodularis, US</li> <li>Vitiligo, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, US</li> <li>Dupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, US</li> <li>Remibrutinib (Novartis) in Chronic Spontaneous Urticaria, US</li> <li>Nemluvio (Galderma) in Prurigo Nodularis, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Biologic Coordinators Across Dermatology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

Key

- MARKET DYNAMIX** Yearly market overview of key indication
- REALTIME DYNAMIX** Quarterly (US) or semi-annual (EU5) indication updates
- LAUNCH DYNAMIX** Monthly benchmark of newly launched products
- PATIENT CHART DYNAMIX** Yearly review of large-scale patient chart audits
- SPECIAL TOPIX** Current events on specific interest areas



## Eosinophilic Esophagitis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Eosinophilic Esophagitis, US</li> <li>Eosinophilic Esophagitis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Eohilia (Takeda) in Eosinophilic Esophagitis, US</li> </ul>

## Inflammatory Bowel Disease

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Crohn's Disease, US</li> <li>Crohn's Disease, EU5</li> <li>Ulcerative Colitis, US</li> <li>Ulcerative Colitis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Entyvio SC (Takeda) in Crohn's Disease, US</li> <li>Tremfya (Janssen) in Crohn's Disease, US*</li> <li>Omvoh (Eli Lilly) in Crohn's Disease, US*</li> <li>Entyvio SC (Takeda) in Ulcerative Colitis, US</li> <li>Omvoh (Eli Lilly) in Ulcerative Colitis, US</li> <li>Skyrizi (AbbVie) in Ulcerative Colitis, US</li> <li>Tremfya (Janssen) in Ulcerative Colitis, US</li> <li>Velsipity (Pfizer) in Ulcerative Colitis, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Inflammatory Bowel Disease New Starts, US</li> <li>Inflammatory Bowel Disease Switching, US</li> <li>Inflammatory Bowel Disease Switching, EU5</li> </ul>

## Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>MASLD/MASH, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Rezdiffra (Madrigal) in MASLD/MASH, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>MASLD/MASH, US</li> </ul>

## Other Gastroenterology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Celiac Disease, US</li> <li>Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Irritable Bowel Syndrome, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Iqirvo (Ipsen) in Primary Biliary Cholangitis, US</li> <li>Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>The Role of Primary Care in Gastroenterology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

### Key

- MARKET DYNAMIX** Yearly market overview of key indication
- REALTIME DYNAMIX** Quarterly (US) or semi-annual (EU5) indication updates
- LAUNCH DYNAMIX** Monthly benchmark of newly launched products
- PATIENT CHART DYNAMIX** Yearly review of large-scale patient chart audits
- SPECIAL TOPIX** Current events on specific interest areas



## Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Ankylosing Spondylitis &amp; nr-AxSpA, US</li> <li>Ankylosing Spondylitis &amp; nr-AxSpA, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Bimzelx (UCB) in Ankylosing Spondylitis &amp; nr-AxSpA, US</li> </ul>

## Lupus

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Systemic Lupus Erythematosus, US</li> <li>Systemic Lupus Erythematosus, EU5</li> <li>Cutaneous Lupus Erythematosus, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US</li> <li>Lupus Nephritis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Gazyva (Genentech) in Lupus Nephritis, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US</li> <li>Moderate to Severe SLE, US</li> <li>Moderate to Severe SLE, EU5</li> </ul>

## Psoriatic Arthritis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Psoriatic Arthritis, EU5</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Psoriatic Arthritis, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Bimzelx (UCB) in Psoriatic Arthritis, US</li> <li>Sotyktu (BMS) in Psoriatic Arthritis, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Psoriatic Arthritis, US</li> </ul>

## Other Rheumatology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Dermatomyositis, US (2024)</li> <li>Giant Cell Arteritis, US (2024)</li> <li>Idiopathic Inflammatory Myopathy, US</li> <li>Polymyalgia Rheumatica, US (2024)</li> <li>Rheumatoid Arthritis, US</li> <li>Rheumatoid Arthritis, EU5</li> <li>Sjogren's Syndrome, US</li> <li>Systemic Sclerosis, US</li> <li>Systemic Sclerosis, EU5 (2024)</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hizentra (CSL) in Dermatomyositis, US*</li> <li>Rinvoq (AbbVie) in Giant Cell Arteritis, US*</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Cell Therapy in Rheumatology, US</li> <li>Feedback from ACR Convergence, US</li> <li>Interstitial Lung Disease in Rheumatology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

### Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Kidney Disease

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Autosomal Dominant Polycystic Kidney Disease, US</li> <li>CKD&amp; DKD, Cross-Specialty Perspective, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hyperkalemia, US</li> <li>Dialysis, US</li> <li>Dialysis, Renal Dietitians, US</li> <li>Dialysis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Xphozah (Ardelyx) in Hyperphosphatemia, US</li> <li>Xphozah (Ardelyx) in Hyperphosphatemia, Renal Dietitians, US</li> <li>Jesduvroq (GSK) in Renal Anemia, US</li> <li>Vafseo (Akebia) in Renal Anemia, US</li> <li>OLC (Unicycive) in Hyperphosphatemia, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Chronic Kidney Disease, Non-Dialysis, Nephrology, US</li> <li>Dialysis, US</li> </ul>
<b>SPECIAL TOPI</b>	<ul style="list-style-type: none"> <li>Hypertension in CKD, US</li> <li>Implications of the Dialysis Bundle (US)</li> <li>ASN Kidney Week Conference, US</li> <li>Buy and Bill in Nephrology Practices, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025, US</li> </ul>

## Lupus Nephritis

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US</li> <li>Lupus Nephritis, EU5</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US</li> </ul>

## Glomerular Diseases

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Complement 3 Glomerulopathy, US</li> <li>Focal Segmental Glomerulosclerosis, US</li> <li>Membranous Nephropathy, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Fabhalta (Novartis) in IgAN, US</li> <li>Atrasentan (Novartis) in IgAN, US*</li> <li>Sibeprenlimab (Otsuka) in IgAN, US*</li> <li>Fabhalta (Novartis) in C3G, US</li> <li>Empaveli (Apellis) in C3G, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Complement 3 Glomerulopathy, US</li> <li>Focal Segmental Glomerulosclerosis, US</li> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> <li>IgA Nephropathy, Japan</li> <li>IgA Nephropathy, China</li> </ul>
<b>PATIENT DYNAMIX</b>	<ul style="list-style-type: none"> <li>IgA Nephropathy, US</li> </ul>

### Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>SPECIAL TOPI</b>	Current events on specific interest areas



## Generalized Myasthenia Gravis

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Generalized Myasthenia Gravis, US</li> <li>Generalized Myasthenia Gravis, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>SC Biologics in Generalized Myasthenia Gravis, US</li> <li>Nipocalimab, in Generalized Myasthenia Gravis, US</li> <li>Uplizna, in Generalized Myasthenia Gravis, US*</li> <li>Biosimilar uptake in Generalized Myasthenia Gravis, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>General Myasthenia Gravis, US</li> </ul>

## Migraine

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Migraine, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Migraine, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Zavzpret (Pfizer) in Acute Migraine, US</li> </ul>

## Alzheimer's Disease

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Alzheimer's Disease, US</li> <li>Alzheimer's Disease, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Leqembi (Eisai/Biogen) in Alzheimer's Disease, US</li> <li>Kisunla (Eli Lilly) in Alzheimer's Disease, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Alzheimer's Disease, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Alzheimer's Disease Modifying Therapies vs. Symptomtics, US</li> </ul>

## Multiple Sclerosis

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Sclerosis, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Sclerosis, US</li> <li>Multiple Sclerosis, Canada</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Ocrevus Zunovo SC (Genentech) in Multiple Sclerosis, US</li> </ul>

## Other Neurology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Chronic Inflammatory Demyelinating Polyneuropathy, US</li> <li>Epilepsy, US</li> <li>Parkinson's Disease, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Practice Dynamix in Neurology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

### Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Diabetic Macular Edema

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Diabetic Macular Edema, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Eylea HD (Regeneron/Bayer) in Diabetic Macular Edema, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Diabetic Macular Edema, US</li> </ul>

## Geographic Atrophy

<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Syfovre (Apellis) and Izervay (Iveric Bio) in Geographic Atrophy, US</li> </ul>
-----------------------	--

## Neovascular Age-Related Macular Degeneration

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Neovascular Age-Related Macular Degeneration, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Neovascular Age-Related Macular Degeneration - Switching, US</li> </ul>

## Other Ophthalmology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Chronic Dry Eye, US</li> <li>Diabetic Retinopathy, US</li> <li>Glaucoma, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Eylea (Regeneron/Bayer) in Retinal Disorders, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Business of Ophthalmology, US</li> <li>Gene Therapies in Retina, US</li> <li>Pipeline Opportunities in Ophthalmology, US</li> <li>Retinal Vein Occlusion, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

### Key

- MARKET DYNAMIX** Yearly market overview of key indication
- REALTIME DYNAMIX** Quarterly (US) or semi-annual (EU5) indication updates
- LAUNCH DYNAMIX** Monthly benchmark of newly launched products
- PATIENT CHART DYNAMIX** Yearly review of large-scale patient chart audits
- SPECIAL TOPIX** Current events on specific interest areas



## Paroxysmal Nocturnal Hemoglobinuria

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Paroxysmal Nocturnal Hemoglobinuria, EU5</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Paroxysmal Nocturnal Hemoglobinuria, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Innovations in PNH (Fabhalta (iptacopan), Voydeya (danicopan), and Piasky (crovalimab)), US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Paroxysmal Nocturnal Hemoglobinuria, US</li> </ul>

## Blood Clotting Disorders

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hemophilia, US</li> <li>Hemophilia, EU5</li> </ul>
-----------------------	---

## Hemoglobinopathies - Sickle Cell Disease and Thalassemia

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Sickle Cell Disease, US</li> <li>Thalassemia, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Casgevy and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Sickle Cell Disease, US</li> <li>Thalassemia, US</li> </ul>


## Other Benign Hematology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Cold Agglutin Disease (CAD)</li> <li>Graft vs. Host Disease (GvHD)</li> <li>Thrombocytopenia (Including ITP and TTP)</li> <li>Warm Autoimmune Hemolytic Anemia (w-AIHA)</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Adoption and Impact of Gene Therapy in Hematology</li> <li>Multi-Specialty Approach to aHUS</li> </ul>

### Key

- MARKET DYNAMIX** Yearly market overview of key indication
- REALTIME DYNAMIX** Quarterly (US) or semi-annual (EU5) indication updates
- LAUNCH DYNAMIX** Monthly benchmark of newly launched products
- PATIENT CHART DYNAMIX** Yearly review of large-scale patient chart audits
- SPECIAL TOPIX** Current events on specific interest areas





## Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at  
[www.clientportal.spherixglobalinsights.com](http://www.clientportal.spherixglobalinsights.com)